Precision Cancer Trials with Immunomodulatory Agents: Personalizing Histology Agnostic Approaches

Marina Baretti, Nilofer Azad

Research output: Contribution to journalReview article

Abstract

Advances in high-throughput technologies have yielded impressive insights into the molecular biology behind cancers, resulting in a powerful ally for the development of biomarkers-selected clinical trials, which are critical for translating our genomic knowledge into clinically meaningful outcomes. "Basket studies" or histology-agnostic clinical trials in biomarker-defined populations represent an important research strategy to continue making progress in this field. The recent accelerated US Food and Drug Administration approvals of anti-programmed death 1 pembrolizumab and nivolumab for mismatch repair-deficient cancers, as well as larotrectinib for cancers carrying TRK fusions, support the fundamental premise that some cancers may be best classified based on molecular phenotype and not site of origin. The studies that were conducted showing the efficacy of this approach serve as validation of the basket study paradigm. In the field of immune oncology, the advent of tumor agnostic strategies represents an important step toward discovering biomarkers of response and elucidating mechanisms of treatment efficacy and resistance across a variety of cancer types. We present a review and discussion of the progress in biomarker-defined approaches to drug development in immunology.

Original languageEnglish (US)
Pages (from-to)287-295
Number of pages9
JournalCancer Journal (United States)
Volume25
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Histology
Biomarkers
Neoplasms
Clinical Trials
Drug Approval
DNA Mismatch Repair
Validation Studies
Allergy and Immunology
Molecular Biology
Technology
Phenotype
Food
Research
Pharmaceutical Preparations
Population

Keywords

  • Agnostic histology
  • biomarkers
  • clinical trials
  • DNA mismatch repair
  • immunotherapy
  • pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Precision Cancer Trials with Immunomodulatory Agents : Personalizing Histology Agnostic Approaches. / Baretti, Marina; Azad, Nilofer.

In: Cancer Journal (United States), Vol. 25, No. 4, 01.07.2019, p. 287-295.

Research output: Contribution to journalReview article

@article{a15dc69fae3a4b48958a776cde2991fa,
title = "Precision Cancer Trials with Immunomodulatory Agents: Personalizing Histology Agnostic Approaches",
abstract = "Advances in high-throughput technologies have yielded impressive insights into the molecular biology behind cancers, resulting in a powerful ally for the development of biomarkers-selected clinical trials, which are critical for translating our genomic knowledge into clinically meaningful outcomes. {"}Basket studies{"} or histology-agnostic clinical trials in biomarker-defined populations represent an important research strategy to continue making progress in this field. The recent accelerated US Food and Drug Administration approvals of anti-programmed death 1 pembrolizumab and nivolumab for mismatch repair-deficient cancers, as well as larotrectinib for cancers carrying TRK fusions, support the fundamental premise that some cancers may be best classified based on molecular phenotype and not site of origin. The studies that were conducted showing the efficacy of this approach serve as validation of the basket study paradigm. In the field of immune oncology, the advent of tumor agnostic strategies represents an important step toward discovering biomarkers of response and elucidating mechanisms of treatment efficacy and resistance across a variety of cancer types. We present a review and discussion of the progress in biomarker-defined approaches to drug development in immunology.",
keywords = "Agnostic histology, biomarkers, clinical trials, DNA mismatch repair, immunotherapy, pembrolizumab",
author = "Marina Baretti and Nilofer Azad",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/PPO.0000000000000390",
language = "English (US)",
volume = "25",
pages = "287--295",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "4",

}

TY - JOUR

T1 - Precision Cancer Trials with Immunomodulatory Agents

T2 - Personalizing Histology Agnostic Approaches

AU - Baretti, Marina

AU - Azad, Nilofer

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Advances in high-throughput technologies have yielded impressive insights into the molecular biology behind cancers, resulting in a powerful ally for the development of biomarkers-selected clinical trials, which are critical for translating our genomic knowledge into clinically meaningful outcomes. "Basket studies" or histology-agnostic clinical trials in biomarker-defined populations represent an important research strategy to continue making progress in this field. The recent accelerated US Food and Drug Administration approvals of anti-programmed death 1 pembrolizumab and nivolumab for mismatch repair-deficient cancers, as well as larotrectinib for cancers carrying TRK fusions, support the fundamental premise that some cancers may be best classified based on molecular phenotype and not site of origin. The studies that were conducted showing the efficacy of this approach serve as validation of the basket study paradigm. In the field of immune oncology, the advent of tumor agnostic strategies represents an important step toward discovering biomarkers of response and elucidating mechanisms of treatment efficacy and resistance across a variety of cancer types. We present a review and discussion of the progress in biomarker-defined approaches to drug development in immunology.

AB - Advances in high-throughput technologies have yielded impressive insights into the molecular biology behind cancers, resulting in a powerful ally for the development of biomarkers-selected clinical trials, which are critical for translating our genomic knowledge into clinically meaningful outcomes. "Basket studies" or histology-agnostic clinical trials in biomarker-defined populations represent an important research strategy to continue making progress in this field. The recent accelerated US Food and Drug Administration approvals of anti-programmed death 1 pembrolizumab and nivolumab for mismatch repair-deficient cancers, as well as larotrectinib for cancers carrying TRK fusions, support the fundamental premise that some cancers may be best classified based on molecular phenotype and not site of origin. The studies that were conducted showing the efficacy of this approach serve as validation of the basket study paradigm. In the field of immune oncology, the advent of tumor agnostic strategies represents an important step toward discovering biomarkers of response and elucidating mechanisms of treatment efficacy and resistance across a variety of cancer types. We present a review and discussion of the progress in biomarker-defined approaches to drug development in immunology.

KW - Agnostic histology

KW - biomarkers

KW - clinical trials

KW - DNA mismatch repair

KW - immunotherapy

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85070194754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070194754&partnerID=8YFLogxK

U2 - 10.1097/PPO.0000000000000390

DO - 10.1097/PPO.0000000000000390

M3 - Review article

C2 - 31335393

AN - SCOPUS:85070194754

VL - 25

SP - 287

EP - 295

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 4

ER -